Core Viewpoint - The study identifies activated ATF6α as a hepatic tumor driver that limits immune surveillance, suggesting it as a potential stratification biomarker for immune checkpoint blockade (ICB) therapy response and a new therapeutic target for hepatocellular carcinoma (HCC) [3][11]. Group 1: Research Findings - Activated ATF6α is linked to aggressive tumor phenotypes in HCC, correlating with reduced patient survival rates, accelerated tumor progression, and local immune suppression [6]. - In mouse models, liver-specific activation of ATF6α leads to progressive hepatitis, characterized by endoplasmic reticulum (ER) stress, immune suppression, and hepatocyte proliferation [6]. - The activation of ATF6α enhances glycolysis and directly inhibits gluconeogenic enzyme FBP1, with restoration of FBP1 expression limiting pathological changes associated with ATF6α activation [6][9]. Group 2: Implications for Treatment - The study suggests that long-term activation of ATF6α induces ER stress, resulting in glycolysis-dependent immune suppression in HCC, making it sensitive to ICB therapy [9]. - In HCC patients, levels of ATF6α activation are significantly higher in those with complete responses to immunotherapy compared to those with weaker responses [7]. - Targeting Atf6 through germline knockout, liver-specific knockout, or delivering therapeutic antisense oligonucleotides (ASO) can suppress HCC in preclinical mouse models [8].

Core Viewpoint - The study reveals that macrophage PD-1 plays a critical role in the intersection of immune checkpoint blockade, energy expenditure, and metabolic dysfunction, providing a new theoretical basis for combating metabolic diseases induced by immune checkpoint inhibitors and high-fat diets [7]. Group 1: Research Findings - The research indicates that anti-PD-1 antibodies target macrophage PD-1, reducing energy expenditure without affecting food intake, thereby increasing susceptibility to obesity and systemic metabolic disorders induced by high-fat diets [4]. - The mechanism involves lipopolysaccharide (LPS) activating Unc-51-like autophagy activating kinase-1 (ULK1) in an mTOR-dependent manner, which phosphorylates PD-1 at the Thr250 site, preventing its ubiquitination and degradation by FBXO38 [4][8]. - Phosphorylated PD-1 interacts with IRE1α, inhibiting its phosphorylation and thereby suppressing inflammation driven by endoplasmic reticulum stress [4][8]. Group 2: Implications - The findings suggest that targeting IRE1α-XBP1 may offer a potential strategy to counteract metabolic dysfunction induced by immune checkpoint inhibitors [8]. - The study's insights into the dual role of macrophage PD-1 could lead to new therapeutic approaches for managing metabolic disorders associated with cancer treatments [7].